Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615433 · ClinicalTrials.gov registry record · Phase 3
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
NCT00615433 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 478 participants.
The verdict
NCT00615433, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
Study Summary
Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
Interventions
- DRUG Olanzapine
- DRUG Placebo comparator
- DRUG Lurasidone
- DRUG Lurasidone 40 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615433
The ClinicalTrials.gov registry entry for NCT00615433 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 478 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Olanzapine is the first listed.
NCT00615433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615433 about?
NCT00615433 is a clinical study titled "Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia". Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
What is the current status of trial NCT00615433?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2008-01. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00615433?
The interventions under investigation include: Olanzapine (DRUG), Placebo comparator (DRUG), Lurasidone (DRUG), Lurasidone 40 mg tablets (DRUG).
Who is sponsoring clinical trial NCT00615433?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.